PHAXIAM Therapeutics SA ADR (PHXM) EBITDA (2016 - 2023)
PHAXIAM Therapeutics SA ADR (PHXM) EBITDA from Jun 30, 2016 to Dec 31, 2023. The TTM PHAXIAM Therapeutics SA ADR (PHXM) EBITDA is -$19M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
PHAXIAM Therapeutics SA ADR (PHXM) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +191.29% |
| 3 Years TTM | -38.84% |
| 5 Years TTM | -23.43% |
| All Time TTM | -7.87% |
Annual EBITDA change of PHAXIAM Therapeutics SA ADR (PHXM)
| Year | EBITDA | Change |
|---|---|---|
| 2023 | -$26M | +8.66% |
| 2022 | -$24M | -55.13% |
| 2021 | -$54M | -35.01% |
| 2020 | -$83M | -1501.60% |
| 2019 | $5.92M | -110.92% |
| 2018 | -$54M | +33.79% |
| 2017 | -$41M | +50.20% |
| 2016 | -$27M | +62.88% |
| 2015 | -$17M | +27.70% |
| 2014 | -$13M | +17.66% |
| 2013 | -$11M | +25.43% |
| 2012 | -$8.79M | +6.15% |
| 2011 | -$8.28M | -0.11% |
| 2010 | -$8.29M | N/A |
Comparison PHAXIAM Therapeutics SA ADR (PHXM) five years EBITDA CAGR with competitors
PHAXIAM Therapeutics SA ADR (PHXM) five years EBITDA CAGR is -23.43%.